Dupixent inhibits the overactive signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two key proteins that contribute to the inflammation that may underlie moderate-to-severe asthma.

Dupixent is commonly used for moderate-to-severe eczema, chronic sinusitis with nasal polyps and asthma. It works by blocking certain proteins in the immune system that trigger inflammation and ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent (dupilumab) in adults ...